We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+2.16%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.73B
AUM Growth
+$336M
Cap. Flow
+$448M
Cap. Flow %
25.88%
Top 10 Hldgs %
59.34%
Holding
67
New
13
Increased
7
Reduced
17
Closed
3

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$166M
2
HRMY icon
Harmony Biosciences
HRMY
+$165M
3
NVAX icon
Novavax
NVAX
+$20M
4
CYTK icon
Cytokinetics
CYTK
+$16.4M
5
MREO
Mereo BioPharma
MREO
+$15.9M

Top Sells

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$7.98M
2
LEGN icon
Legend Biotech
LEGN
+$7.57M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$4.7M
4
GLMD icon
Galmed Pharmaceuticals
GLMD
+$4.11M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 91.47%
2 Financials 6.31%
3 Materials 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORTX
51
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.45M 0.31%
132,574
– –
ETNB
52
DELISTED
89bio
ETNB
$4.7M 0.27%
+183,042
New +$5.81M
BDTX icon
53
Black Diamond Therapeutics
BDTX
$110M
$4.4M 0.25%
145,417
-4,932
-3% -$150K
ACRS icon
54
Aclaris Therapeutics
ACRS
$799M
$4.23M 0.24%
1,647,214
– –
RVMD icon
55
Revolution Medicines
RVMD
$42.5B
$3.46M 0.2%
99,517
-100,001
-50% -$2.77M
YARW
56
Yarrow Bioscience, Inc. Common Stock
YARW
$113M
$3.02M 0.17%
506
-506
-50% -$2.95M
CNST
57
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.84M 0.16%
140,298
– –
TECX
58
Tectonic Therapeutic
TECX
$581M
$2.69M 0.16%
17,185
-3,950
-19% -$796K
ATRC icon
59
AtriCure
ATRC
$2.07B
$2.58M 0.15%
64,573
– –
LITS
60
Lite Strategy Inc
LITS
$31.6M
$2.55M 0.15%
40,848
-13,256
-25% -$799K
RNAC icon
61
Cartesian Therapeutics
RNAC
$266M
$2.35M 0.14%
31,573
-43,620
-58% -$3.34M
TCDA
62
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.58M 0.09%
174,763
-1
-0% -$15
MTCR
63
DELISTED
Metacrine, Inc. Common Stock
MTCR
$1.5M 0.09%
+146,426
New +$1.5M
DTIL icon
64
Precision BioSciences
DTIL
$207M
$864K 0.05%
4,675
– –
DBVT
65
DBV Technologies
DBVT
$847M
– –
-27,000
Closed -$1.19M
GLMD icon
66
Galmed Pharmaceuticals
GLMD
$4.83M
– –
-4,778
Closed -$4.11M
VSTM icon
67
Verastem
VSTM
$557M
– –
-386,628
Closed -$7.98M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Vivo Capital held 67 positions worth $1.73B, up 24% from $1.39B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Vivo Capital deployed $448M of net new capital in Q3 2020, opening 13 new positions and adding to 7 existing holdings. Its largest new stake was ALX Oncology: 4,220,048 shares worth $159M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Legend Biotech, an estimated $7.57M trimmed.

  • Vivo Capital's largest Q3 2020 buy was ALX Oncology: 4,220,048 shares worth $159M.
  • Vivo Capital added most to Mereo BioPharma in Q3 2020, an estimated $15.9M increase.
  • Vivo Capital's biggest Q3 2020 reduction was Legend Biotech, cutting an estimated $7.57M.
  • Vivo Capital fully exited Verastem in Q3 2020, selling an estimated $7.98M.
  • Vivo Capital's ten largest holdings make up 59% of its $1.73B portfolio in Q3 2020.
  • Vivo Capital opened 13 new positions and closed 3 in Q3 2020.
  • Vivo Capital's portfolio value rose 24% quarter-over-quarter to $1.73B.

Based on Vivo Capital's 13F filing for Q3 2020, filed 13 Nov 2020.